- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04988204
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
Pilot Study: Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a rapidly growing epidemic worldwide and is an increasingly important etiology of chronic liver disease and hepatocellular carcinoma. NAFLD affects approximately 90 million people in the United States (US) amounting to an annual cost of $100 billion yearly. It is projected to become the leading cause of liver transplantation in the US by 2030 and is associated with significant morbidity and mortality. NAFLD is a spectrum of liver diseases, ranging from simple steatosis (nonalcoholic fatty liver, NAFL) to hepatic steatosis associated with inflammation (nonalcoholic steatohepatitis, NASH), which can be associated with liver scarring (hepatic fibrosis) and cirrhosis. There are limited therapeutic options that have been shown to effectively reduce or reverse the progression of disease.
Lifestyle modification is the backbone of therapy, but difficult to achieve. A modest amount of weight loss of approximately 3% can reduce liver steatosis and a 10% weight loss can reduce the NASH and improve liver fibrosis. The American Association of the Study of Liver Diseases (AASLD) guidelines state that "a combination of a hypocaloric diet (daily reduction by 500-1000 kcal) and moderate intensity exercise is the best likelihood of sustaining weight loss over time." There are several barriers to adopting a healthy lifestyle involving both patient and physician limitations. The aim of this study is to engage patients in a lifestyle intervention program that has already been shown to be successful in achieving weight loss goals and adopting healthier lifestyle patterns.
The CDC Diabetes Prevention Program, (DPP) was a large (n=3,234) multicenter study aimed to evaluate the effect of lifestyle intervention or treatment with metformin on the incidence of type 2 diabetes (T2DM). Lifestyle intervention reduced the incidence of T2DM by 58% (95% CI, 48-66%) and metformin reduced the incidence by 31% (95% CI, 17-43%) as compared to placebo. To prevent one case of diabetes over three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. The CDC DPP program has been adapted and tested in the multiple different community and state-wide programs including the YMCA, WorkWellNYC and NYS DPP. In these real-world models, the life style intervention program has been delivered in a group-based format by DPP lifestyle coaches. These programs have been successful like that of the randomized trial and improvements were sustainable at 6 and 12 month follow up after completion of the program. The program is now available and reimbursable through Medicare (Medicare Diabetes Prevention Program).
In this pilot study, the researchers will enroll 20 patients with NAFLD in an adapted DPP program and follow study participants for 1 year. The rationale for the proposed research is to apply the DPP to NAFLD because of the close relationship with Diabetes and determine the real-world outcome of the DPP program on weight loss in patients with NAFLD. If the researchers illustrate that weight loss can be achieved and is sustainable in patients with NAFLD enrolled in lifestyle intervention programs, the researchers can develop innovative approaches to deliver such a program nationwide in a cost-effective and sustainable manner.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10003
- Mount Sinai Union Square
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- diagnosis of NAFLD, defined by the presence of hepatic steatosis with vibration controlled transient elastography (VCTE) controlled attenuation parameter (CAP) measurement over 240dB/m, or liver biopsy showing macrovesicular steatosis in ≥ 5% of hepatocytes.
- patients were 18 years and older,
- fluent in English (the program could only be conducted in English by the DPP-certified coach),
- able to meet program scheduling requirements, and able to participate in physical activity.
Exclusion Criteria:
- additional causes of liver disease such as viral hepatitis, biliary obstruction, hepatocellular carcinoma, Wilson's disease, Budd Chiari Syndrome, autoimmune hepatitis, alcoholic liver disease or alcohol use (>20g/day women, >30g/day men),
- aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values >300 U/L,
- using steatogenic medications (amiodarone, methotrexate, tamoxifen, and corticosteroids),
- pregnant,
- a history of liver transplantation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Treatment Arm
Patients enrolled in 1 year program
|
The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes.
Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of participants in the program at the end of the study
기간: 12 months
|
Retention defined as number of patients in the program at the end of the study
|
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in Weight
기간: baseline and 12 months
|
Change in Weight at 12 months as compared to baseline
|
baseline and 12 months
|
Hepatic steatosis via Fibroscan
기간: Baseline
|
Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter.
|
Baseline
|
Hepatic steatosis via Fibroscan
기간: 6 months
|
Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter .
|
6 months
|
Hepatic steatosis via Fibroscan
기간: 12 months
|
Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter.
|
12 months
|
Glycosylated A1C
기간: Baseline
|
Glycosylated A1C in assessing metabolic comorbidity
|
Baseline
|
Glycosylated A1C
기간: 6 months
|
Glycosylated A1C in assessing metabolic comorbidity
|
6 months
|
Glycosylated A1C
기간: 12 months
|
Glycosylated A1C in assessing metabolic comorbidity
|
12 months
|
Lipid levels
기간: Baseline
|
Lipid levels in assessing metabolic comorbidity
|
Baseline
|
Lipid levels
기간: 6 months
|
Lipid levels in assessing metabolic comorbidity
|
6 months
|
Lipid levels
기간: 12 months
|
Lipid levels in assessing metabolic comorbidity
|
12 months
|
Liver enzymes levels
기간: Baseline
|
Liver enzymes levels for ALT, AST, and ALP
|
Baseline
|
Liver enzymes levels
기간: 6 months
|
Liver enzymes levels for ALT, AST, and ALP
|
6 months
|
Liver enzymes levels
기간: 12 months
|
Liver enzymes levels for ALT, AST, and ALP
|
12 months
|
Bilirubin level
기간: Baseline
|
Liver enzyme level for Bilirubin
|
Baseline
|
Bilirubin level
기간: 6 months
|
Liver enzyme level for Bilirubin
|
6 months
|
Bilirubin level
기간: 12 months
|
Liver enzyme level for Bilirubin
|
12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Amreen Dinani, Icahn School of Medicine, Division of Liver Diseases
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- GCO 18-1283
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Diabetes Prevention Program에 대한 임상 시험
-
University of Texas Southwestern Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD)초대로 등록
-
Children's Hospital Medical Center, CincinnatiNational Institute of Mental Health (NIMH)완전한
-
Stanford UniversityTobacco Related Disease Research Program빼는
-
UConn HealthUniversity of Texas at Austin; Oregon Social Learning Center초대로 등록
-
Massachusetts General Hospital완전한
-
University of LiverpoolLondon School of Hygiene and Tropical Medicine; National Institute of Mental Health (NIMH)완전한
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes...완전한
-
Children's Health모집하지 않고 적극적으로
-
Centre Hospitalier Universitaire de la Réunion모병